Nutlin-3

For research use only. Not for use in humans.

製品コードS1061

分子量(MW)：581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

サイズ

価格(税別)

在庫

10mM (1mL in DMSO)	JPY 32700	あり
5mg	JPY 20200	あり
10mg	JPY 30200	あり
25mg	JPY 63400	あり
100mg	JPY 163000	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(36)

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明

ターゲット

Mdm2 ^[5]
(Cell-free assay)

180 nM

体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. ^[1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. ^[2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. ^[3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. ^[4]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MCF7	NEP1cm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfEN4NqPcLizszN	M3vLb\|Q5yqCq		M2rPNIJtd2OtczCyO{1QUENvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iY3;tdIFz[WKuZTD0c{B1cGG2IH;mJIJie2GuIHzleoVtew>?	NI\UT5UzPjN3MEW2OS=>
NP69	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTNzLk[5xtEzNjV2IN88US=>	NIfKcYozPjJ3MkW3OS=>
NP460	MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLpcFJLUUN3ME2yNk45PcLzMT6xPEDPxE1?	MljvNlYzPTJ3N{W=
C666-1	M3HHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTF7Lkm1xtE5Njl\|IN88US=>	NF\GWZIzPjJ3MkW3OS=>
C666-1	NYLmXlYyS2WubDDWbYFjcWyrdImgRZN{[Xl?	MUixNEDDvU1?	NWT3U\|FyPDhiaB?=	MWfEUXNQ	MlvLd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw	Mmq4NlYzPTJ3N{W=
C666-1	NEDrd25HfW6ldHnvckBCe3OjeR?=	NXnnenl7OTBiwsXN	MlvFNlQhcA>?	NFrYeZVFVVOR	MmSxZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z	NIr6[WwzPjJ3MkW3OS=>
C666-1	MYHBdI9xfG:\|aYOgRZN{[Xl?	MkOwNVAhyrWP	NXz0SWZpPDhxN{KgbC=>	MWrEUXNQ	MmnNd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:gZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz	Mo\SNlYzPTJ3N{W=
A549	NIroSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoHNNlQhcA>?		MlG3TWM2OD1zNz62PEDDuSB2LkWyJO69VQ>?	MXSyOlEzPTJ\|MB?=
A549-NTC	M2jBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXLk[lBrOjRiaB?=		MWrJR\|UxRTF7LkSyJOKyKDFwOU[g{txO	NY\3UYk3OjZzMkWyN\|A>
A549-920	M2m3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NULLR2VlOjRiaB?=		NWLzXGRXUUN3ME2zN{45PSEEsTC0Mlg1KM7:TR?=	NFuyb5YzPjF{NUKzNC=>
CRL-5908	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3\Ze\|I1KGh?		MnrFTWM2OD1\|OD63NUDDuSB{LkSzJO69VQ>?	MYiyOlEzPTJ\|MB?=
L6	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jFUVExyqEQvF5CpC=>	M1HYd\|I1NzR6L{eyJIg>	M1jac2ROW09?	MVnpcohq[mm2czDj[YxteyCycn;sbYZmemG2aX;uJIFv\CCmaX\m[ZJmdnSrYYTpc44>	M3nKZ\|I2QDdzN{m0
C2C12	NX\PdFN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHH3SlQyOMLizszNxsA>	MV2yOE81QC95MjDo	M3LUO2ROW09?	MYXpcohq[mm2czDj[YxteyCycn;sbYZmemG2aX;uJIFv\CCmaX\m[ZJmdnSrYYTpc44>	MmPaNlU5PzF5OUS=
MCF-7	M3:wb2Z2dmO2aX;uJGF{e2G7	NYXHe45yOTEEoN88US=>		M{nqRmROW09?	M4r4colvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>?	NVPDdoFQOjV5MEK3NFM>
DU4475	NV;E[G42TnWwY4Tpc44hSXO\|YYm=	M2jqZVUwOTBxMkCg{txO	MlfpNlTDqGh?		NWSxRWxy\G:5boLl[5Vt[XSnczDUc4NiNTFiZH;z[UBl\XCnbnTlcpRtgQ>?	MmrVNlU2PDdzN{S=
SMMC-7721	NUPwbWZiTnWwY4Tpc44hSXO\|YYm=	MnW4NVAh\|ryP	MWG0PEBp	MorVSG1UVw>?	MYfjZZV{\XNiRF7BJGRUSiCmYX3h[4U>	MojVNlU2PDR\|NkG=
SMMC-7721	M3fFVGZ2dmO2aX;uJGF{e2G7	NX;ROow4OTBizszN	MlXNOFghcA>?	M2\mfWROW09?	NYjuT3NVcW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>?	MYeyOVU1PDN4MR?=
SMMC-7721	MY\GeY5kfGmxbjDBd5NigQ>?	MV2xNEDPxE1?	MnzHOFghcA>?	NXzHfJBHTE2VTx?=	NUf4NVlUcW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mxsBKTk6EMdMgcXJPSQ>?	NXe2RoNEOjV3NESzOlE>
SMMC-7721	NX35W\|RnTnWwY4Tpc44hSXO\|YYm=	NWXzUXpQOTBizszN	MV:zOkBp	MYPEUXNQ	MmezZ4F2e2W\|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY>	NHvINI0zPTV2NEO2NS=>
MCF-7	M4nH[2Z2dmO2aX;uJGF{e2G7	M1PidlExyqEQvF2=	NXrXb\|VUOC1{NDDo		MV\pcoR2[2W\|IIC1N{BidmRicEKxM2NqeDF?	M1[3TlI2PDh{M{ez
OVCAR10	MlrNSpVv[3Srb36gRZN{[Xl?	NVPlPHE4OTEEoN88US=>	MkXSNlFpyqB?	M{XON2ROW09?	NVLWc\|d[cW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>?	NFTGTmEzPTR{NkW0PC=>
NCI-H23	NFjUdlBHfW6ldHnvckBCe3OjeR?=	MoLYNVDDqM7:TR?=	M3PYelIycMLi	NYHZfohOTE2VTx?=	NHzSU5dqdmO{ZXHz[ZMheDV\|IIDyc5RmcW5ibHX2[Yx{	NVrTOGFDOjV2Mk[1OFg>
A2780	MoHqSpVv[3Srb36gRZN{[Xl?	M1XFe\|ExyqEQvF2=	MWiyNYjDqA>?	NXLEWXRZTE2VTx?=	MkjlbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=>	M1n2TlI2PDJ4NUS4
NCI-H23	Mn;lSpVv[3Srb36gRZN{[Xl?	NF7v[5UyOMLizszN	MlvGNlFpyqB?	MVHEUXNQ	NIXmZ2pl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=>	MUCyOVQzPjV2OB?=
A2780	NIrsUZdHfW6ldHnvckBCe3OjeR?=	MX[xNOKh\|ryP	MlW1NlFpyqB?	M3j4U2ROW09?	NUDpcot{\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM>	NF20UnYzPTR{NkW0PC=>
HCT116	NEHmTZJHfW6ldHnvckBCe3OjeR?=	MoXhNVAhyrWP	Ml\UNlQhcA>?		Mn3wZ4F2e2W\|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW\|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6	MWmyOVM5ODB3NR?=
MCF-10CA1a	M2T2d2Z2dmO2aX;uJGF{e2G7	NY\rPJlSOTEEoN88US=>	NHK3To01QCCq	M4jqcWROW09?	Mn;VbY5pcWKrdIOgZoF{[WxiaX72ZZNqd25iYX7kJJJm\HWlZXSgWGdHNc7{Mz3pcoR2[2WmIHnueoF{cW:wIITvJIJie2GuIHzleoVtew>?	NXT5b4g6OjV{NUe3Nlk>
MCF-10A1	NFrSR2ZHfW6ldHnvckBCe3OjeR?=	M2DCeVExyqEQvF2=	NWfkNZd5OjRxNEigbC=>	MUHEUXNQ	MVrpcohq[mm2czDtbYdz[XSrb36gc4Yhdm:{bXHsJIJz\WG\|dDDldIl1cGWuaXHsxsA>	MlHxNlUzPTd5Mkm=
MCF-10CA1a	M3LNe2Z2dmO2aX;uJGF{e2G7	M1fYOlExyqEQvF2=	M2jHPFI1KGh?	NWr2eXh[TE2VTx?=	NYH5Z2d2\GWlcnXhd4V{KHSqZTDUS2Yu\|rJ\|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh\|rMEoEO=	NGD3T4szPTJ3N{eyPS=>
MCF-10CA1a	NYDyW5NLTnWwY4Tpc44hSXO\|YYm=	NFuzXmYyOMLizszN	MX6yOEBp	MYDEUXNQ	NXH5NGR6cW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO\|aX;u	MX2yOVI2Pzd{OR?=
SK-BR-7	Ml;VSpVv[3Srb36gRZN{[Xl?	NVjUV\|J5OTEEoN88US=>	MXuyOEBp	NHvTbWdFVVOR	M3vlOolvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?=	M1\PfVI2OjV5N{K5
SUM102PT	MWrGeY5kfGmxbjDBd5NigQ>?	MXyxNOKh\|ryP	Mn:zNlQhcA>?	MoHESG1UVw>?	MWXpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25?	NIXkXJkzPTJ3N{eyPS=>
RAW 264.7	NXfWcHpUTnWwY4Tpc44hSXO\|YYm=	MVixNOKh\|ryP	MXqzNEBucW5?		MUjwdoV3\W62czD0bIUheDV\|IILl[JVkfGmxbjDpckBz\XOyb37z[UB1dyCOUGO=	NHvnepgzPTF5MkW0Oy=>
RAW 264.7	NWLS[XVTTnWwY4Tpc44hSXO\|YYm=	Moj3NVDDqM7:TR?=	MVmzNEBucW5?		M4Thb5Jm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm=	MkjzNlUyPzJ3NEe=
RAW 264.7	MWfGeY5kfGmxbjDBd5NigQ>?	MYWxNOKh\|ryP	M{PFclMxKG2rbh?=		NVnQNYhEcW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh	MlrONlUyPzJ3NEe=
MCF7	MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFLBNlUzNjViwsXN	NHjCSIM2KGR?	M3TlXGROW09?	NHLtcW5{\W6\|aYTpfoV{KE2FRkegeI8hWEGUUDDpcohq[mm2aX;u	M{TUUVI2ODh3OUCy
MCF7	NFLlSlVHfW6ldHnvckBCe3OjeR?=	MYGyMlUhyrWP	MlHuOFghcA>?	NGXwcphFVVOR	MXnk[YNz\WG\|ZYOgeIhmKGixbX;sc4dwfXNiRGPCJJJmeGGrcjDmdoVyfWWwY3nldy=>	MlHMNlUxQDV7MEK=
ACHN	NGHuOVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MYOwMlUuOTBizszN	NVfyc3VUOC14IHS=	MXrEUXNQ	NUfBUZdGcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M4PHbFI2ODZ5N{i3
Caki-2	MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NX21bWp4OC53LUGwJO69VQ>?	MmjqNE03KGR?	NEHjZpJFVVOR	Ml\tbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M2foNFI2ODZ5N{i3
A498	NFLWfolE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXnubohXOC53LUGwJO69VQ>?	M3G3PVAuPiCm	NGW4b25FVVOR	NVyxUlI{cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MnXoNlUxPjd5OEe=
115	NGXOSnpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M2XPNlAvPS1zMDFOwG0>	NEnPTW4xNTZiZB?=	NET5dINFVVOR	NVf0V3ZTcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NHXZdVUzPTB4N{e4Oy=>
117	MkW4R4VtdCCYaXHibYxqfHliQYPzZZk>	Mn;tNE42NTFyIN88US=>	NU\DN\|F1OC14IHS=	NVG1PXZmTE2VTx?=	MoPzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NH65[FEzPTB4N{e4Oy=>
ACHN	MkC5SpVv[3Srb36gRZN{[Xl?	NEP4OmcxNjVxMT:1JO69VQ>?	MoDuOFghcA>?	NEjxbnhFVVOR	NXjpeGRydGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG=	NVHMS2hJOjVyNke3PFc>
Caki-2	M1z6S2Z2dmO2aX;uJGF{e2G7	M{f4[FAvPS9zL{Wg{txO	M2jxdlQ5KGh?	NFnwT5BFVVOR	MYjs[YFleyC2bzDpcoNz\WG\|ZXSg[ZhxemW\|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>?	M1e4PVI2ODZ5N{i3
A498	M4fN[mZ2dmO2aX;uJGF{e2G7	NULFVldIOC53L{GvOUDPxE1?	NUPtSHQ2PDhiaB?=	MWjEUXNQ	NYO1eZNVdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG=	NWTIXFY1OjVyNke3PFc>
115	NHuycmRHfW6ldHnvckBCe3OjeR?=	MVWwMlUwOS93IN88US=>	M3r1T\|Q5KGh?	NFHzeI5FVVOR	NWjrTI1rdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG=	M2rJU\|I2ODZ5N{i3
ACHN	M4jwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jOPFUh\|ryP	MWe0PEBp	MmWwSG1UVw>?	M1zGfIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=>	NUDzepl2OjVyNke3PFc>
Caki-2	MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLxe\|I2KM7:TR?=	MmXZOFghcA>?	NHvMdnZFVVOR	MUTpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2wrC=	NHvucGQzPTB4N{e4Oy=>
A498	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfjfWhIPSEQvF2=	MWm0PEBp	NV;lfo9UTE2VTx?=	M2C2TYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=>	MXWyOVA3Pzd6Nx?=
115	NUDRTG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PDV\|Uh\|ryP	MWC0PEBp	NUXlR41{TE2VTx?=	MYHpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2wrC=	MkXFNlUxPjd5OEe=
ACHN	NET6V21HfW6ldHnvckBCe3OjeR?=	NVrYeoRYPSEQvF2=	NYP6W\|NUPDhiaB?=	NXTQcFV2TE2VTx?=	MlXnbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?=	M3Ha[FI2ODZ5N{i3
Caki-2	NWnxSYNoTnWwY4Tpc44hSXO\|YYm=	M1vye\|Uh\|ryP	MXK0PEBp	MUDEUXNQ	MXnpcoR2[2W\|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi	M{TKXVI2ODZ5N{i3
A498	MnzCSpVv[3Srb36gRZN{[Xl?	NYjVdpZRPSEQvF2=	NUfiXlM3PDhiaB?=	MkfoSG1UVw>?	NWLvO5JlcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=>	M{nRZVI2ODZ5N{i3
115	NFzjc29HfW6ldHnvckBCe3OjeR?=	M{HzWlUh\|ryP	NFTqO3Q1QCCq	MoPCSG1UVw>?	MkfObY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?=	NXi4UZg4OjVyNke3PFc>
MOLM-13	MVzGeY5kfGmxbjDBd5NigQ>?	Mn\lOuKh\|ryP	NH7vWIQxNThiaB?=	MoXkSG1UVw>?	M1nGZolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>?	NXHhRWVkOjR6OEWwPFI>
MOLM-13	NXzKVXRWTnWwY4Tpc44hSXO\|YYm=	MUW2xsDPxE1?	MmXoOkBp	NIOzNmJFVVOR	NI\3eIRmdmijbnPld{B1cGViYXPleJlt[XSrb36gc4YhcGm\|dH;u[UBJOkJiYX7kJIhm[XRic3jvZ4sheHKxdHXpcpMhUHOyMkegZY5lKEi\|cEmw	M2LYPVI1QDh3MEiy
HepG2	M2n4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2q3fVczKGh?	NY\scHZZTE2VTx?=	MUDJR\|UxRTN3Lki2JOKyKDJwOTFOwG0>	MUOyOFg5PDhyOR?=
HepG2/As	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUnuV5Y5PzJiaB?=	MnvHSG1UVw>?	NWXtXY83UUN3ME22PE4yOyEEsTC5MlYh\|ryP	MmXKNlQ5QDR6MEm=
SMMC7721	NV24VFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVHDVZlIPzJiaB?=	Mo\rSG1UVw>?	MkHBTWM2OD1\|MT6yPEDDuSB2LkKg{txO	NUfxSVFnOjR6OES4NFk>
SMMC7721/Ac	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlOxO\|IhcA>?	Ml\WSG1UVw>?	MUfJR\|UxRTV3LkKxJOKyKDVwMEOg{txO	Mkn6NlQ5QDR6MEm=
Huh-7	M1e2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYPp[YV1PzJiaB?=	MoXpSG1UVw>?	NH3HV3VKSzVyPUOzMlk3KMLzIEOuPUDPxE1?	NFrMNlUzPDh6NEiwPS=>
Hep3B	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHjBN4k4OiCq	MVrEUXNQ	M3r1NGlEPTB;MkCuNVghyrFiMT64OEDPxE1?	NXvobpI6OjR6OES4NFk>
HepG2	M2WybmFxd3C2b4Ppd{BCe3OjeR?=				MWTpcoR2[2W\|IHHwc5B1d3Orcx?=	MnPQNlQ5QDR6MEm=
SMMC7721	MUXBdI9xfG:\|aYOgRZN{[Xl?				NXLwVXZbcW6mdXPld{BieG:ydH;zbZM>	M1;qdlI1QDh2OEC5
Huh-7	MmDlRZBweHSxc3nzJGF{e2G7				MknrbY5lfWOnczDhdI9xfG:\|aYO=	MYOyOFg5PDhyOR?=
Hep3B	M4\lNmFxd3C2b4Ppd{BCe3OjeR?=				NHG5WIxqdmS3Y3XzJIFxd3C2b4Ppdy=>	NHnkfnAzPDh6NEiwPS=>
U2OS	M{S5bmZ2dmO2aX;uJGF{e2G7	NGXie5kzOCEQvF2=	NY\rUm5wOjRiaB?=		MkLVbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhSkOOMlGxMEBDS0y[TNMgZY5lSkOOVx?=	NVOz[JNyOjR6NkeyOVk>
AML2	M1W5OWFxd3C2b4Ppd{BCe3OjeR?=	NXzjNVhPOi9zMDFOwG0>	MWmyOE81QCCq		M4LFb4lv\HWlZYOgZZBweHSxc3nz	Mn\ONlQ3PTl5NEm=
MOML13	NFf2Z41CeG:ydH;zbZMhSXO\|YYm=	MnPRNk8yOCEQvF2=	NITNWWYzPC92ODDo		NWDycIxPcW6mdXPld{BieG:ydH;zbZM>	MXiyOFY2QTd2OR?=
AML2	M2XSWmZ2dmO2aX;uJGF{e2G7	M{f5eVEx\|ryP	MVuyM\|QhcA>?		NV[4RWlpcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM>	MXmyOFY2QTd2OR?=
AML3	M3HScGZ2dmO2aX;uJGF{e2G7	MlvaNVDPxE1?	MoD5Nk81KGh?		NUHYU4tqcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM>	MVuyOFY2QTd2OR?=
MOML13	MUTGeY5kfGmxbjDBd5NigQ>?	NVPESpBiOTEQvF2=	NV75[YZtOi92IHi=		M4jub4lv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz	NYDnPZdNOjR4NUm3OFk>
BeWo	NGjDZopHfW6ldHnvckBCe3OjeR?=	MnXPN\|AhyrWP	M37kNFI1KGh?		MVzpcoNz\WG\|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy=	NGfvS\|kzPDR7OEG1OC=>
BeWo	NXvSOIZmSXCxcITvd4l{KEG\|c3H5	MmLEN\|AhyrWP	NGDYdIMzPCCq		MlTFbY5kemWjc3XzJIFxd3C2b4Ppdy=>	NYHscIdXOjR2OUixOVQ>
OCI	NY\FeHdSTnWwY4Tpc44hSXO\|YYm=	MoPJNVAh\|ryP	MUeyOEBp		MnjleZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w	MmrGNlQ1PzN3NkK=
MOLM	NEm0S2hHfW6ldHnvckBCe3OjeR?=	M3T2b\|ExKM7:TR?=	Mk\GNlQhcA>?		M1LiS5VxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?=	M1fIclI1PDd\|NU[y
U2OS	M4LmSWZ2dmO2aX;uJGF{e2G7	NFLWTGQzOCEQvF2=	NFLofJgzPCCq		Mm\xbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG\|IITo[UBxPTNicILveIVqdg>?	Mny2NlQ{PjZyMEe=
RKO	Mk\GSpVv[3Srb36gRZN{[Xl?	NHXESGMzOCEQvF2=	M2r5dlI1KGh?		NIW4[phqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw	NVTrS2RsOjR\|Nk[wNFc>
U2OS	M{fzS2Z2dmO2aX;uJGF{e2G7	MX2yNEDPxE1?	NXnl[3IzOjRiaB?=		MVvpcoR2[2W\|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?=	MnzsNlQ{PjZyMEe=
RKO	MoWxSpVv[3Srb36gRZN{[Xl?	M13WXVIxKM7:TR?=	Ml;JNlQhcA>?		MWjpcoR2[2W\|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?=	NWXDephJOjR\|Nk[wNFc>
SMMC-7721	NWP0d5ExS2WubDDWbYFjcWyrdImgRZN{[Xl?	Mmr2NU4zPS1{MDFOwG0>	MUiyOE81QC95MjDo	MkXjSG1UVw>?	M4LWfYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5	MUmyOFI5PjNzMh?=
HuH-7	MmL1R4VtdCCYaXHibYxqfHliQYPzZZk>	Mn\qNU4zPS1{MDFOwG0>	M3fKUlI1NzR6L{eyJIg>	M2m2RmROW09?	NH;hPZRqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=>	MVeyOFI5PjNzMh?=
SMMC-7721	MWPBdI9xfG:\|aYOgRZN{[Xl?	NHe2dIQzOCEQvF2=	M1HjWlQ5KGh?	NFThTXVFVVOR	M3nNeYlv\HWlZYOgZZBweHSxc3nz	NWXPeYdEOjR{OE[zNVI>
HuH-7	NEfMPZpCeG:ydH;zbZMhSXO\|YYm=	M1TQOFIxKM7:TR?=	MYC0PEBp	NVXBPGc3TE2VTx?=	M{HWSolv\HWlZYOgZZBweHSxc3nz	MlzwNlQzQDZ\|MUK=
SMMC-7721	Mm\CSpVv[3Srb36gRZN{[Xl?	M3TleFExKM7:TR?=	M3;UN\|M3KGh?	M2TEWWROW09?	MkfK[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW\|c3nvckBt\X[nbDDv[kBxcG:\|cHjvMXNmejN7Mj3wOVM>	M2jHOVI1Ojh4M{Gy
HuH-7	MoS0SpVv[3Srb36gRZN{[Xl?	MXmxNEDPxE1?	NX3ONW03OzZiaB?=	MYnEUXNQ	M1\jWoRwf25vcnXneYxifGW\|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ\|OUKtdFU{	MYCyOFI5PjNzMh?=
AT2	NVLpSItbTnWwY4Tpc44hSXO\|YYm=	MlHQOU8yOCEQvF2=			M4f1doxm[WS\|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO\|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li	MVuyOFI1ODJyMx?=
REH	NVrtcnZZTnWwY4Tpc44hSXO\|YYm=	NILXRnI2NzFyIN88US=>			NHXEbHdt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW\|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?=	MU[yOFI1ODJyMx?=
UoCB6	M{jMXGZ2dmO2aX;uJGF{e2G7	Ml7EOU8yOCEQvF2=			MXns[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>?	M{L5TVI1OjRyMkCz
AT2	NWH1eo96S2WubDDWbYFjcWyrdImgRZN{[Xl?	MoLTNE0zPSEQvF2=			NHnPOYZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	MUSyOFI1ODJyMx?=
REH	M3roT2NmdGxiVnnhZoltcXS7IFHzd4F6	M3fueFAuOjVizszN			NGfjdFVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NU\tZWJvOjR{NECyNFM>
UoCB6	MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MUiwMVI2KM7:TR?=			M{T4PYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MljxNlQzPDB{MEO=
A2780	NF7YelRHfW6ldHnvckBCe3OjeR?=	M2WzflUwOTBxMkCg{txO	NWHUVXZ{OjRiaB?=		M2nkRpVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi	NGfYNZUzPDF\|NkG0Oy=>
H460	NFfifoNHfW6ldHnvckBCe3OjeR?=	MVW1M\|ExNzJyIN88US=>	MUWyOEBp		NYX2cppKfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC=	NWH3eHR[OjRzM{[xOFc>
Lovo	NH\Oe5FHfW6ldHnvckBCe3OjeR?=	MXG1M\|ExNzJyIN88US=>	NFzlfJkzPCCq		NUPWZmx2fXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC=	NH7yOlczPDF\|NkG0Oy=>
A2780	NUn5UIpqSXCxcITvd4l{KEG\|c3H5	MoDNOU8yOC9{MDFOwG0>	M{P4dFI1KGh?		MYLlcohidmOnczDhdI9xfG:\|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=>	MUeyOFE{PjF2Nx?=
H460	NYi4UmVRSXCxcITvd4l{KEG\|c3H5	NUG3cZZwPS9zMD:yNEDPxE1?	MYeyOEBp		MW\lcohidmOnczDhdI9xfG:\|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=>	MoO2NlQyOzZzNEe=
Lovo	NY[4N2E4SXCxcITvd4l{KEG\|c3H5	NEnlN\|E2NzFyL{KwJO69VQ>?	MoW1NlQhcA>?		NGLiSFFmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>?	M{PPWFI1OTN4MUS3

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	MDM2 / p53 / ALKBH2 / p21 / PUMA; PubMed: 23258843 Neuro Oncol CCF-STTG1 cells were treated with the MDM2 antagonist nutlin-3 (0–8 µM) for 24h before cell lysates were collected for western blotting. RRM1 / RRM2 / p53R2 / p21 / p53 / pS6 / S6; PubMed: 28507282 Oncotarget (A) Rh18 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. (B) Rh30 cells were treated with different concentrations of nutlin-3 as indicated for 24 hr. Total proteins were extracted for immunoblotting of RRM1, RRM2, γH2AX, p21, p53R2, p53, S6, pS6-235/6 and 4E-BP1. GAPDH and Actin served as loading controls.	23258843 28507282
Immunofluorescence	Lamin A / Lamin C / p16 / H3K9me3; PubMed: 30728349 Cell Death Dis c Immunofluorescence images of nuclear deformation and p16 expression after Nutlin-3 treatment for different time period. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were subjected to immunofluorescence staining for Lamin A/C (Red), p16 (Green), and counterstained with DAPI (Blue). dImmunofluorescence images of nuclear deformation and decreased expression of H3K9me3 in HCT p53+/− cells (left). Counting of histone H3K9me3-positive cells (middle) and signal intensities (right) on the basis of IF staining. HCT p53+/− cells were treated with Nutlin-3 (1 μM) for different time (24, 48 h). After treatment, cells were IF stained with Lamin A/C (Red), H3K9me3 (Green), and counterstained with DAPI (Blue). *P < 0.05. Merlin / cyclin D1 / p53 / MDM2; PubMed: 30274821 EBioMedicine The changes in the subcellular localization of proteins in response to Nutlin-3. Nuclear merlin was indicated with white arrows. Scale bar = 50 μm. p53; PubMed: 24286312 BMB Rep The subcellular localization of p53 was detected under immunofluorescence microscope (1,000×). The cells were treated as indicated and stained for p53 (red). Nuclei were counterstained with DAPI (blue).	30728349 30274821 24286312
Growth inhibition assay	Cell viability; PubMed: 29286113 Mol Med Rep Inhibitory effect of nutlin-3 for the cell proliferation after cultivate cells at different concentration for three times (24, 48 and 72 h), respectively.	29286113

体内試験

Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. ^[1]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	- 合併 Biacore study: Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm²). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験： ^[1]	- 合併細胞株： HCT116, RKO, SJSA-1, SW480, and MDA-MB-435 濃度： Dissolved in DMSO, final concentrations ~ 30 μM 反応時間： 8, 24, and 48 hours 実験の流れ： Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy. (参考用のみ)
動物試験： ^[1]	- 合併動物モデル： Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells 投薬量： 200 mg/kg 投与方法： Orally, twice a day (参考用のみ)

参考

- 合併

溶解度 (25°C)

体外	DMSO	100 mg/mL (171.96 mM)
	Ethanol	30 mg/mL (51.59 mM)
	Water	Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Nutlin-3 SDFをダウンロードする

分子量	581.5
化学式	C₃₀H₃₀Cl₂N₄O₄
CAS No.	890090-75-2
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	COC1=CC(=C(C=C1)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(Cl)C=C4)C5=CC=C(Cl)C=C5)OC(C)C

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?
回答：
It is a racemate.

Mdm2シグナル伝達経路

相関Mdm2製品

Idasanutlin (RG-7388)

Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity.
MI-773 (SAR405838)

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
A-1210477

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
NSC 207895

NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.
Nutlin-3a

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.

Features:Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Nutlin-3b

Nutlin-3b is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.
YH239-EE

YH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer.

研究分野別

製品類型

Nutlin-3

文献中Selleckの製品使用例(36)

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Nutlin-3 SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

技術サポート

よくある質問（FAQ）

Mdm2シグナル伝達経路

相関Mdm2製品